Table 4. Percentage* of CNV affected cases in cohort (TCGA).
| Project | Study name | TCF3 | TWIST2 | KLF10 | SOX9 | FOXQ1 | FOXF2 | FOXC1 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gains | Losses | Gains | Losses | Gains | Losses | Gains | Losses | Gains | Losses | Gains | Losses | Gains | Losses | ||
| TCGA-BLCA | Bladder Urothelial Carcinoma | 1.23 | 21.08 | 20.59 | 0.49 | 12.75 | 0.74 | ||||||||
| TCGA-BRCA | Breast invasive carcinoma | 1.68 | 14.74 | 18.66 | 1.12 | 20.06 | 2.05 | ||||||||
| TCGA-CESC | Cervical squamous cell carcinoma and endocervical adenocarcinoma | 2.72 | 14.97 | 0.68 | 25.85 | ||||||||||
| TCGA-CHOL | Cholangiocarcinoma | 16.67 | 0 | ||||||||||||
| TCGA-ESCA | Esophageal carcinoma | 1.09 | 13.04 | 2.17 | 15.22 | 15.22 | 2.17 | 13.59 | 4.89 | 8.15 | 16.3 | 7.61 | 16.3 | 7.61 | 16.3 |
| TCGA-HNSC | Head and Neck squamous cell carcinoma | 0.77 | 11.13 | 1.34 | 17.47 | ||||||||||
| TCGA-LIHC | Liver hepatocellular carcinoma | 13.75 | 0.27 | ||||||||||||
| TCGA-LUAD | Lung Adenocarcinoma | 11.89 | 2.14 | 10.53 | 0.78 | ||||||||||
| TCGA-LUSC | Lung Squamous Cell Carcinoma | 1.99 | 11.75 | 1.79 | 19.12 | 14.94 | 1.59 | 15.14 | 1.39 | ||||||
| TCGA-OV | Ovarian serous cystadenocarcinoma | 1.37 | 58.97 | 11.28 | 21.2 | 29.74 | 5.98 | 27.52 | 1.71 | 26.32 | 12.14 | 26.32 | 12.31 | 25.81 | 12.14 |
| TCGA-SARC | Sarcoma | 10 | 15 | 4.23 | 22.31 | 12.31 | 2.69 | ||||||||
| TCGA-SKCM | Skin Cutaneous Melanoma | 11.97 | 1.28 | 11.11 | 1.5 | 11.11 | 1.5 | 10.9 | 1.07 | ||||||
| TCGA-UCEC | Uterine Corpus Endometrial Carcinoma | 0.2 | 18.43 | ||||||||||||
| TCGA-UCS | Uterine Carcinosarcoma | 1.79 | 51.79 | 16.07 | 0 | 19.64 | 0 | 8.93 | 10.71 | 8.93 | 10.71 | ||||
| TCGA-UVM | Uveal Melanoma | 15.19 | 0 | 8.93 | 10.71 | ||||||||||
*We have shown changes of only 10% and above in either of a pair of Gain or Loss.